|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.220 SEK | +0.16% |
|
-1.93% | -38.07% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceuticals | 208M | 61.14M | 5.68M | 94.63M | 57.46M | |||||
Total Assets | 472M | 324M | 177M | 136M | 141M | |||||
Interest Expense | -370K | -297K | -199K | -10.48M | -17.99M | |||||
Income Tax Expense | - | - | - | - | - | |||||
CAPEX | -708K | -2.88M | -293K | -199K | - | |||||
EBT | 51.78M | -113M | -178M | -83.13M | -110M | |||||
D&A | 3.22M | 3.72M | 4.32M | 4.58M | 4.32M | |||||
Operating Income | 52.58M | -113M | -181M | -75.11M | -93.4M | |||||
Net Income | 51.78M | -113M | -178M | -83.13M | -110M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | 4.22M | 94.63M | 57.46M | |||||
United Kingdom | 208M | 61.14M | 1.46M | - | - | |||||
Sweden | - | - | - | - | - | |||||
Total Assets | 51.01M | 54.87M | 53.53M | 56.65M | 52.34M | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
- Stock Market
- Stocks
- IRLAB A Stock
- Financials IRLAB Therapeutics AB
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
